In Reply We thank Litman for the careful reading of our article1 and his commentary. Emphasizing the risk for patients with Parkinson disease to withdraw from or rapidly decrease participating in dopamine replacement therapy, we fell into the trap of the common confusion between “neuroleptic malignant syndrome” and “malignant hyperthermia syndrome.” Despite some similarities, the 2 syndromes are indeed different. We recommend the review of Litman et al2 for more information about malignant hyperthermia and how to avoid confusing it with neuroleptic malignant syndrome.
Damier P, Al-Hashel J. Confusing Terminology—Neuroleptic Malignant Syndrome vs Malignant Hyperthermia—Reply. JAMA Neurol. 2017;74(8):1013. doi:10.1001/jamaneurol.2017.0825
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: